Advances in Oncology Extend Lives, but Lead to New Safety Considerations for Sponsors and Investigators
From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations. Left unaddressed, they could undermine a trial or put patient safety at risk. In this paper, we discuss some of those issues and how sponsors can best address them.
The WIRB-Copernicus Group® (WCG) is the world’s largest and most trusted provider of regulatory and ethical review services for human research. For more information, visit www.wcgclinical.com/.